Drugs Information:
Brivaracetam
Basic Information
|
||
ID | DDInter239 | |
Drug Type | small molecule | |
Molecular Formula | C11H20N2O2 | |
Molecular Weight | 212.289 | |
CAS Number | 357336-20-0 | |
Description | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. | |
ATC Classification | N03AX23 | |
IUPAC Name | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide | |
InChI | MSYKRHVOOPPJKU-BDAKNGLRSA-N | |
Canonical SMILES | CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB PharmGKB Wikipedia ChEMBL ZINC |
Interactions with
Brivaracetam
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|